메뉴 건너뛰기




Volumn 17, Issue 9, 2016, Pages 1215-1223

Prevention and management of treatment failure to new oral hepatitis C drugs

Author keywords

daclatasvir; drug resistance; Hepatitis C; paritaprevir; simeprevir; sofosbuvir; treatment failure

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; PARITAPREVIR; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA;

EID: 84975322552     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1182156     Document Type: Review
Times cited : (52)

References (111)
  • 1
    • 84876149257 scopus 로고    scopus 로고
    • Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence
    • K.Mohd-Hanafiah, J.Groeger, A.Flaxman, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.
    • (2013) Hepatology , vol.57 , pp. 1333-1342
    • Mohd-Hanafiah, K.1    Groeger, J.2    Flaxman, A.3
  • 2
    • 84921060015 scopus 로고    scopus 로고
    • Global distribution and prevalence of hepatitis C virus genotypes
    • J.Messina, I.Humphreys, A.Flaxman, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87.
    • (2015) Hepatology , vol.61 , pp. 77-87
    • Messina, J.1    Humphreys, I.2    Flaxman, A.3
  • 3
    • 84914150658 scopus 로고    scopus 로고
    • Global epidemiology and genotype distribution of the hepatitis C virus infection
    • This manuscript is the first to highlight globally that seroprevalence does not reflect viremia, and that estimates of chronic hepatitis C must rely better on HCV-RNA instead of HCV antibodies since 30% of seroreactive persons are in fact cured, so far mostly spontaneously
    • E.Gower, C.Estes, S.Blach, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(suppl):45–57.• This manuscript is the first to highlight globally that seroprevalence does not reflect viremia, and that estimates of chronic hepatitis C must rely better on HCV-RNA instead of HCV antibodies since 30% of seroreactive persons are in fact cured, so far mostly spontaneously.
    • (2014) J Hepatol , vol.61 , pp. 45-57
    • Gower, E.1    Estes, C.2    Blach, S.3
  • 4
    • 84920265713 scopus 로고    scopus 로고
    • Estimates on HCV disease burden worldwide - filling the gaps
    • H.Wedemeyer, G.Dore, J.Ward Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat. 2015;22(suppl 1):1–5.
    • (2015) J Viral Hepat , vol.22 , pp. 1-5
    • Wedemeyer, H.1    Dore, G.2    Ward, J.3
  • 5
    • 84975279936 scopus 로고    scopus 로고
    • Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis
    • Forthcoming
    • J.Riou, M.Aït-Ahmed, A.Blake, et al. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat. Forthcoming.
    • J Viral Hepat
    • Riou, J.1    Aït-Ahmed, M.2    Blake, A.3
  • 6
    • 84894880765 scopus 로고    scopus 로고
    • Evaluation of liver disease progression in the German Hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection
    • M.Wiese, J.Fisher, M.Lobermann, et al. Evaluation of liver disease progression in the German Hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.
    • (2014) Hepatology , vol.59 , pp. 49-57
    • Wiese, M.1    Fisher, J.2    Lobermann, M.3
  • 8
    • 84871055775 scopus 로고    scopus 로고
    • A comparative risk assessment of burden of disease and injury attributable to 67 risk factor and risk factors cluster in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
    • S.Lim, T.Vos, A.Flaxman, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factor and risk factors cluster in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–2260.
    • (2012) Lancet , vol.380 , pp. 2224-2260
    • Lim, S.1    Vos, T.2    Flaxman, A.3
  • 9
    • 84931560807 scopus 로고    scopus 로고
    • Recommendations on treatment of hepatitis C 2015
    • EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
    • (2015) J Hepatol , vol.63 , pp. 199-236
  • 11
    • 84879420038 scopus 로고    scopus 로고
    • The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
    • R.Bartenschlager, V.Lohmann, F.Penin. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11:482–496.
    • (2013) Nat Rev Microbiol , vol.11 , pp. 482-496
    • Bartenschlager, R.1    Lohmann, V.2    Penin, F.3
  • 12
    • 84902439547 scopus 로고    scopus 로고
    • Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world?
    • I.Gentile, A.Buonomo, E.Zappulo, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther. 2014;12:763–773.
    • (2014) Expert Rev Anti Infect Ther , vol.12 , pp. 763-773
    • Gentile, I.1    Buonomo, A.2    Zappulo, E.3
  • 13
    • 84898990930 scopus 로고    scopus 로고
    • New hepatitis C therapies: the toolbox, strategies, and challenges
    • This is an updated review on clinical virology of HCV with special focus on therapeutic implications of resistance-associated variants and HCV genotype diversity
    • J.M.Pawlotsky. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–1192.• This is an updated review on clinical virology of HCV with special focus on therapeutic implications of resistance-associated variants and HCV genotype diversity.
    • (2014) Gastroenterology , vol.146 , pp. 1176-1192
    • Pawlotsky, J.M.1
  • 14
    • 84929054425 scopus 로고    scopus 로고
    • Continued progress against hepatitis C infection
    • H.Convjeevaram. Continued progress against hepatitis C infection. JAMA. 2015;313:1716–1717.
    • (2015) JAMA , vol.313 , pp. 1716-1717
    • Convjeevaram, H.1
  • 15
    • 84944390503 scopus 로고    scopus 로고
    • HCV treatment: is it possible to cure all HCV patients?
    • A.Muir, S.Naggie. HCV treatment: is it possible to cure all HCV patients? Clin Gastroenterol Hepatol. 2015;13:2166–2172.
    • (2015) Clin Gastroenterol Hepatol , vol.13 , pp. 2166-2172
    • Muir, A.1    Naggie, S.2
  • 16
    • 84946595410 scopus 로고    scopus 로고
    • Bradyarrhythmias associated with sofosbuvir treatment
    • This is the first and most complete report of cardiac dysfunction using sofosbuvir
    • H.Fontaine, D.Duboc, S.Pol. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373:1886–1888.• This is the first and most complete report of cardiac dysfunction using sofosbuvir.
    • (2015) N Engl J Med , vol.373 , pp. 1886-1888
    • Fontaine, H.1    Duboc, D.2    Pol, S.3
  • 17
    • 84938201899 scopus 로고    scopus 로고
    • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
    • T.Ahmad, P.Yin, J.Saffitz, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.
    • (2015) Hepatology , vol.62 , pp. 409-416
    • Ahmad, T.1    Yin, P.2    Saffitz, J.3
  • 18
    • 84951304878 scopus 로고    scopus 로고
    • Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use
    • J.Dyson, J.Hutchinson, L.Harrison, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64:234–238.
    • (2016) J Hepatol , vol.64 , pp. 234-238
    • Dyson, J.1    Hutchinson, J.2    Harrison, L.3
  • 19
    • 84939829307 scopus 로고    scopus 로고
    • Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child–Pugh B compensated cirrhosis
    • Forthcoming
    • V.Soriano, P.Barreiro, C.De Mendoza, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child–Pugh B compensated cirrhosis. Antivir Ther. Forthcoming.
    • Antivir Ther
    • Soriano, V.1    Barreiro, P.2    De Mendoza, C.3
  • 20
    • 84975296572 scopus 로고    scopus 로고
    • Hypoglycemia in a diabetic patient during hepatitis C therapy
    • Forthcoming
    • V.Soriano, P.Barreiro, C.De Mendoza. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. Forthcoming.
    • Hepatology
    • Soriano, V.1    Barreiro, P.2    De Mendoza, C.3
  • 21
    • 84940591343 scopus 로고    scopus 로고
    • Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient
    • R.Helmers, T.Byme, L.Wesselius, et al. Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient. Mayo Clin Proc. 2015;90:1294–1297.
    • (2015) Mayo Clin Proc , vol.90 , pp. 1294-1297
    • Helmers, R.1    Byme, T.2    Wesselius, L.3
  • 22
    • 84975315174 scopus 로고    scopus 로고
    • Safety and tolerability of direct-acting antiviral agents in the new era of hepatitis C therapy
    • Forthcoming
    • D.Banerjee, K.Reddy. Safety and tolerability of direct-acting antiviral agents in the new era of hepatitis C therapy. Aliment Pharmacol Therap. Forthcoming.
    • Aliment Pharmacol Therap
    • Banerjee, D.1    Reddy, K.2
  • 23
    • 84954399628 scopus 로고    scopus 로고
    • The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
    • This review updates current knowledge and therapeutic implications of HCV resistance-associated variants
    • C.Sarrazin. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.•• This review updates current knowledge and therapeutic implications of HCV resistance-associated variants.
    • (2016) J Hepatol , vol.64 , pp. 486-504
    • Sarrazin, C.1
  • 24
    • 84932613679 scopus 로고    scopus 로고
    • Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era?
    • N.Terrault. Difficult-to-cure populations with chronic hepatitis C: vanishing in the direct-acting antiviral era? Hepatology. 2015;62:4–7.
    • (2015) Hepatology , vol.62 , pp. 4-7
    • Terrault, N.1
  • 25
    • 84941563178 scopus 로고    scopus 로고
    • Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C
    • P.Barreiro, P.Labarga, J.V.Fernandez-Montero, et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol. 2015;71:63–66.
    • (2015) J Clin Virol , vol.71 , pp. 63-66
    • Barreiro, P.1    Labarga, P.2    Fernandez-Montero, J.V.3
  • 26
    • 84957438363 scopus 로고    scopus 로고
    • New hepatitis C therapies for special patient populations
    • This review updates the characteristics of patient populations that challenge the most the success of DAA combinations
    • V.Soriano, P.Labarga, C.De Mendoza, et al. New hepatitis C therapies for special patient populations. Exp Opin Pharmacother. 2016;17:217–229.• This review updates the characteristics of patient populations that challenge the most the success of DAA combinations.
    • (2016) Exp Opin Pharmacother , vol.17 , pp. 217-229
    • Soriano, V.1    Labarga, P.2    De Mendoza, C.3
  • 27
    • 84963736042 scopus 로고    scopus 로고
    • Comprehensive screening for naturally-occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A and NS5B genes in worldwide isolates from viral genotypes 1-6
    • Forthcoming
    • J.Patiño-Galindo, K.Salvatierra, F.González-Candelas, et al. Comprehensive screening for naturally-occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A and NS5B genes in worldwide isolates from viral genotypes 1-6. Antimicrob Agents Chemother. Forthcoming.
    • Antimicrob Agents Chemother
    • Patiño-Galindo, J.1    Salvatierra, K.2    González-Candelas, F.3
  • 28
    • 79959401302 scopus 로고    scopus 로고
    • Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients
    • A.Treviño, C.De Mendoza, P.Parra, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV coinfected patients. Antiviral Ther. 2011;16:413–416.
    • (2011) Antiviral Ther , vol.16 , pp. 413-416
    • Treviño, A.1    De Mendoza, C.2    Parra, P.3
  • 29
    • 84975279902 scopus 로고    scopus 로고
    • Baseline prevalence and emergence of protease inhibitors resistance mutations following treatment in chronic HCV genotype 1 infected individuals
    • Forthcoming
    • L.Nguyen, E.Gray, J.Dean, et al. Baseline prevalence and emergence of protease inhibitors resistance mutations following treatment in chronic HCV genotype 1 infected individuals. Antivir Ther. Forthcoming.
    • Antivir Ther
    • Nguyen, L.1    Gray, E.2    Dean, J.3
  • 30
    • 84922318694 scopus 로고    scopus 로고
    • Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
    • C.Sarrazin, E.Lathouwers, M.Peeters, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antivir Res. 2015;116:10–16.
    • (2015) Antivir Res , vol.116 , pp. 10-16
    • Sarrazin, C.1    Lathouwers, E.2    Peeters, M.3
  • 31
    • 84903701056 scopus 로고    scopus 로고
    • Update on hepatitis C virus resistance to direct-acting antiviral agents
    • E.Poveda, D.Wyles, A.Mena, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antivir Res. 2014;108:181–191.
    • (2014) Antivir Res , vol.108 , pp. 181-191
    • Poveda, E.1    Wyles, D.2    Mena, A.3
  • 32
    • 80055075318 scopus 로고    scopus 로고
    • NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5
    • S.Vallet, F.Viron, C.Henquell, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther. 2011;16:1093–1102.
    • (2011) Antivir Ther , vol.16 , pp. 1093-1102
    • Vallet, S.1    Viron, F.2    Henquell, C.3
  • 33
    • 84873041135 scopus 로고    scopus 로고
    • Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment
    • D.Bartels, J.Sullivan, E.Zhang, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544–1553.
    • (2013) J Virol , vol.87 , pp. 1544-1553
    • Bartels, D.1    Sullivan, J.2    Zhang, E.3
  • 34
    • 84858415895 scopus 로고    scopus 로고
    • Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, and NS5A inhibitor
    • Z.Plaza, V.Soriano, E.Vispo, et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, and NS5A inhibitor. Antivir Ther. 2012;17:921–926.
    • (2012) Antivir Ther , vol.17 , pp. 921-926
    • Plaza, Z.1    Soriano, V.2    Vispo, E.3
  • 35
    • 84875804486 scopus 로고    scopus 로고
    • Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors
    • D.Hernandez, N.Zhou, J.Ueland, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.
    • (2013) J Clin Virol , vol.57 , pp. 13-18
    • Hernandez, D.1    Zhou, N.2    Ueland, J.3
  • 36
    • 84975315288 scopus 로고    scopus 로고
    • Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals
    • Forthcoming
    • L.Nguyen, N.Hall, D.Sheerin, et al. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir Ther. Forthcoming.
    • Antivir Ther
    • Nguyen, L.1    Hall, N.2    Sheerin, D.3
  • 37
    • 84975315291 scopus 로고    scopus 로고
    • Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
    • Forthcoming
    • Z.Chen, H.Li, H.Ren, et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. Forthcoming.
    • Sci Rep
    • Chen, Z.1    Li, H.2    Ren, H.3
  • 38
    • 58149388300 scopus 로고    scopus 로고
    • Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients
    • T.Kuntzen, J.Timm, A.Berical, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48:1769–1778.
    • (2008) Hepatology , vol.48 , pp. 1769-1778
    • Kuntzen, T.1    Timm, J.2    Berical, A.3
  • 39
    • 84898645159 scopus 로고    scopus 로고
    • Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors
    • V.Di Maio, V.Cento, C.Mirabelli, et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014;58:2781–2797.
    • (2014) Antimicrob Agents Chemother , vol.58 , pp. 2781-2797
    • Di Maio, V.1    Cento, V.2    Mirabelli, C.3
  • 40
    • 84873604286 scopus 로고    scopus 로고
    • Antiviral resistance and the future landscape of hepatitis C virus infection therapy
    • D.Wyles. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis. 2013;207(suppl 1):33–39.
    • (2013) J Infect Dis , vol.207 , pp. 33-39
    • Wyles, D.1
  • 41
    • 84927798764 scopus 로고    scopus 로고
    • Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
    • O.Lenz, T.Verbinnen, B.Fevery, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015;62:1008–1014.
    • (2015) J Hepatol , vol.62 , pp. 1008-1014
    • Lenz, O.1    Verbinnen, T.2    Fevery, B.3
  • 42
    • 84940942461 scopus 로고    scopus 로고
    • Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir
    • P.Krishnan, R.Tripathi, G.Schnell, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–5454.
    • (2015) Antimicrob Agents Chemother , vol.59 , pp. 5445-5454
    • Krishnan, P.1    Tripathi, R.2    Schnell, G.3
  • 43
    • 84939260843 scopus 로고    scopus 로고
    • Resistance analysis of virologic failure in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir ± ribavirin: the C-WORTHY study
    • S.Black, I.Pak, P.Ingravallo, et al. Resistance analysis of virologic failure in hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir ± ribavirin: the C-WORTHY study. J Hepatol. 2015;62(suppl):677–678.
    • (2015) J Hepatol , vol.62 , pp. 677-678
    • Black, S.1    Pak, I.2    Ingravallo, P.3
  • 44
    • 84921276609 scopus 로고    scopus 로고
    • Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subject treated with sofosbuvir in phase 2 and 3 clinical trials
    • E.Svarovskaia, H.Dvory-Sobol, H.Parkin, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subject treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–1674.
    • (2014) Clin Infect Dis , vol.59 , pp. 1666-1674
    • Svarovskaia, E.1    Dvory-Sobol, H.2    Parkin, H.3
  • 45
    • 84943815570 scopus 로고    scopus 로고
    • Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy
    • C.Hedskog, H.Dvory-Sobol, V.Gontcharova, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22:871–881.
    • (2015) J Viral Hepat , vol.22 , pp. 871-881
    • Hedskog, C.1    Dvory-Sobol, H.2    Gontcharova, V.3
  • 46
    • 84920945807 scopus 로고    scopus 로고
    • Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
    • E.Donaldson, P.Harrington, J.O´Rear, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61:56–65.
    • (2015) Hepatology , vol.61 , pp. 56-65
    • Donaldson, E.1    Harrington, P.2    O´Rear, J.3
  • 47
    • 84941917709 scopus 로고    scopus 로고
    • Hepatitis C virus drug resistance-associated substitutions: state of the art summary
    • This position paper records the most relevant information on HCV drug resistance
    • E.Lontok, P.Harrington, A.Howe, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.•• This position paper records the most relevant information on HCV drug resistance.
    • (2015) Hepatology , vol.62 , pp. 1623-1632
    • Lontok, E.1    Harrington, P.2    Howe, A.3
  • 48
    • 84964762303 scopus 로고    scopus 로고
    • Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir based-regimens
    • P.Krishnan, R.Tripathi, G.Schnell, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir- and dasabuvir based-regimens. J Hepatol. 2015;62:1008–1014.
    • (2015) J Hepatol , vol.62 , pp. 1008-1014
    • Krishnan, P.1    Tripathi, R.2    Schnell, G.3
  • 49
    • 84879683134 scopus 로고    scopus 로고
    • Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials
    • J.Sullivan, S.De Meyer, D.Bartels, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–229.
    • (2013) Clin Infect Dis , vol.57 , pp. 221-229
    • Sullivan, J.1    De Meyer, S.2    Bartels, D.3
  • 50
    • 84918577537 scopus 로고    scopus 로고
    • Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience
    • D.Jensen, J.O´Leary, P.Pockros, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real world experience. Hepatology. 2014;60(supp l):219A.
    • (2014) Hepatology , vol.60 , pp. 219
    • Jensen, D.1    O´Leary, J.2    Pockros, P.3
  • 51
    • 84923037769 scopus 로고    scopus 로고
    • Evaluation of sofosbuvir and simeprevir –based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population
    • D.Dieterich, B.Bacon, S.Flamm, et al. Evaluation of sofosbuvir and simeprevir –based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. Hepatology. 2014;60(suppl):220A.
    • (2014) Hepatology , vol.60 , pp. 220
    • Dieterich, D.1    Bacon, B.2    Flamm, S.3
  • 52
  • 53
    • 84946945495 scopus 로고    scopus 로고
    • Management of direct antiviral agent failures
    • M.Buti, M.Riveiro-Barciela, R.Esteban. Management of direct antiviral agent failures. J Hepatol. 2015;63:1511–1522.
    • (2015) J Hepatol , vol.63 , pp. 1511-1522
    • Buti, M.1    Riveiro-Barciela, M.2    Esteban, R.3
  • 54
    • 84900339263 scopus 로고    scopus 로고
    • ION-1 Investigators. Ledipasvir and sofosbuvir for untreated genotype 1 infection
    • N.Afdhal, S.Zeuzem, P.Kwo, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
    • (2014) N Engl J Med , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3
  • 55
    • 84898669547 scopus 로고    scopus 로고
    • ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
    • N.Afdhal, K.Reddy, D.Nelson, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl Med. 2014;370:1483–1493.
    • (2014) N Engl Med , vol.370 , pp. 1483-1493
    • Afdhal, N.1    Reddy, K.2    Nelson, D.3
  • 56
    • 84948705255 scopus 로고    scopus 로고
    • Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial
    • G.Everson, W.Towner, M.Davis, et al. Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:818–826.
    • (2015) Ann Intern Med , vol.163 , pp. 818-826
    • Everson, G.1    Towner, W.2    Davis, M.3
  • 57
    • 84856159009 scopus 로고    scopus 로고
    • Preliminary study of two antiviral agents for hepatitis C genotype 1
    • A.Lok, D.Gardiner, E.Lawitz, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–224.
    • (2012) N Engl J Med , vol.366 , pp. 216-224
    • Lok, A.1    Gardiner, D.2    Lawitz, E.3
  • 58
    • 84906814530 scopus 로고    scopus 로고
    • All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
    • M.Manns, S.Pol, I.Jacobson, et al. All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–1605.
    • (2014) Lancet , vol.384 , pp. 1597-1605
    • Manns, M.1    Pol, S.2    Jacobson, I.3
  • 59
    • 84894621765 scopus 로고    scopus 로고
    • Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
    • E.Lawitz, F.Poordad, P.Pangs, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
    • (2014) Lancet , vol.383 , pp. 515-523
    • Lawitz, E.1    Poordad, F.2    Pangs, P.3
  • 60
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sosfosbuvir for previously treated or untreated chronic HCV infection
    • M.Sulkowski, D.Gardiner, M.Rodriguez-Torres, et al. Daclatasvir plus sosfosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–221.
    • (2014) N Engl J Med , vol.370 , pp. 211-221
    • Sulkowski, M.1    Gardiner, D.2    Rodriguez-Torres, M.3
  • 61
    • 84925364974 scopus 로고    scopus 로고
    • All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study
    • D.Nelson, J.Cooper, J.Lalezari, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015;61:1127–1135.
    • (2015) Hepatology , vol.61 , pp. 1127-1135
    • Nelson, D.1    Cooper, J.2    Lalezari, J.3
  • 62
    • 84975301024 scopus 로고    scopus 로고
    • Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection
    • Forthcoming
    • C.Landaverde, J.Wells, R.Hamner, et al. Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol. Forthcoming.
    • Expert Rev Gastroenterol Hepatol
    • Landaverde, C.1    Wells, J.2    Hamner, R.3
  • 63
    • 84939833091 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1
    • D.Wyles, P.Ruane, M.Sulkowski, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
    • (2015) N Engl J Med , vol.373 , pp. 714-725
    • Wyles, D.1    Ruane, P.2    Sulkowski, M.3
  • 64
    • 84925607745 scopus 로고    scopus 로고
    • Virological response after 6 week triple drug regimens for hepatitis C: a proof-of-concept phase 2 cohort study
    • A.Kohli, A.Osinusi, Z.Sims, et al. Virological response after 6 week triple drug regimens for hepatitis C: a proof-of-concept phase 2 cohort study. Lancet. 2015;385:1107–1113.
    • (2015) Lancet , vol.385 , pp. 1107-1113
    • Kohli, A.1    Osinusi, A.2    Sims, Z.3
  • 65
    • 84943230055 scopus 로고    scopus 로고
    • The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment
    • B.Lam, T.Jeffers, Z.Younoszai, et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol. 2015;8:298–312.
    • (2015) Ther Adv Gastroenterol , vol.8 , pp. 298-312
    • Lam, B.1    Jeffers, T.2    Younoszai, Z.3
  • 66
    • 84904568743 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
    • H.Günthard, J.Aberg, J.Eron, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:410–425.
    • (2014) JAMA , vol.312 , pp. 410-425
    • Günthard, H.1    Aberg, J.2    Eron, J.3
  • 67
    • 84943328674 scopus 로고    scopus 로고
    • Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients
    • J.Dietz, S.Susser, C.Berkowski, et al. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS One. 2015;10:e0134395.
    • (2015) PLoS One , vol.10 , pp. 134395
    • Dietz, J.1    Susser, S.2    Berkowski, C.3
  • 68
    • 84939271310 scopus 로고    scopus 로고
    • The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- ribavirin
    • C.Sarrazin, H.Dvory-Sobol, E.Svarovskaia, et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- ribavirin. J Hepatol. 2015;62(suppl):620.
    • (2015) J Hepatol , vol.62 , pp. 620
    • Sarrazin, C.1    Dvory-Sobol, H.2    Svarovskaia, E.3
  • 69
    • 84975320514 scopus 로고    scopus 로고
    • Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy
    • Forthcoming
    • I.Ozeki, T.Nakajima, M.Yamaguchi, et al. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir-daclatasvir combination therapy. Hepatol Res. Forthcoming.
    • Hepatol Res
    • Ozeki, I.1    Nakajima, T.2    Yamaguchi, M.3
  • 70
    • 84975315249 scopus 로고    scopus 로고
    • Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen
    • Forthcoming
    • C.Hézode, S.Chevaliez, G.Scoazec, et al. Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. Forthcoming.
    • Hepatology
    • Hézode, C.1    Chevaliez, S.2    Scoazec, G.3
  • 71
    • 45749088957 scopus 로고    scopus 로고
    • Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
    • V.Soriano, A.Perelson, F.Zoulim. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother. 2008;62:1–4.
    • (2008) J Antimicrob Chemother , vol.62 , pp. 1-4
    • Soriano, V.1    Perelson, A.2    Zoulim, F.3
  • 72
    • 84926667719 scopus 로고    scopus 로고
    • Global origin and transmission of HCV non-structural protein 3 Q80K polymorphism
    • R.McCloskey, R.Liang, J.Joy, et al. Global origin and transmission of HCV non-structural protein 3 Q80K polymorphism. J Infect Dis. 2015;211:1288–1295.
    • (2015) J Infect Dis , vol.211 , pp. 1288-1295
    • McCloskey, R.1    Liang, R.2    Joy, J.3
  • 73
    • 84894271490 scopus 로고    scopus 로고
    • In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
    • X.Tong, S.Le Pogam, L.Li, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209:668–675.
    • (2014) J Infect Dis , vol.209 , pp. 668-675
    • Tong, X.1    Le Pogam, S.2    Li, L.3
  • 74
    • 84975314675 scopus 로고    scopus 로고
    • L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions
    • Forthcoming
    • E.Svarovskaia, E.Gane, H.Dvory-Sobol, et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis. Forthcoming.
    • J Infect Dis
    • Svarovskaia, E.1    Gane, E.2    Dvory-Sobol, H.3
  • 75
    • 84884158588 scopus 로고    scopus 로고
    • Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3
    • E.Tapper, N.Afdhal. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20:669–677.
    • (2013) J Viral Hepat , vol.20 , pp. 669-677
    • Tapper, E.1    Afdhal, N.2
  • 76
    • 84885949784 scopus 로고    scopus 로고
    • Antiviral activity and resistance of HCV NS5A replication complex inhibitors
    • N.Gao. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Op Virol. 2013;5:514–520.
    • (2013) Curr Op Virol , vol.5 , pp. 514-520
    • Gao, N.1
  • 77
    • 84900992889 scopus 로고    scopus 로고
    • Sofosbuvir and ribavirin in HCV genotypes 2 and 3
    • S.Zeuzem, G.Dusheiko, R.Salupere, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.
    • (2014) N Engl J Med , vol.370 , pp. 1993-2001
    • Zeuzem, S.1    Dusheiko, G.2    Salupere, R.3
  • 78
    • 84975315205 scopus 로고    scopus 로고
    • Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)
    • Forthcoming
    • V.Leroy, P.Angus, J.P.Bronowicki, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. Forthcoming.
    • Hepatology
    • Leroy, V.1    Angus, P.2    Bronowicki, J.P.3
  • 79
    • 84952909361 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
    • G.Foster, N.Afdhal, S.Roberts, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
    • (2015) N Engl J Med , vol.373 , pp. 2608-2617
    • Foster, G.1    Afdhal, N.2    Roberts, S.3
  • 80
    • 84941943566 scopus 로고    scopus 로고
    • HCV targeting of patients with cirrhosis
    • P.Ferenci, K.Kozbial, M.Mandorfer, et al. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015–1022.
    • (2015) J Hepatol , vol.63 , pp. 1015-1022
    • Ferenci, P.1    Kozbial, K.2    Mandorfer, M.3
  • 81
    • 84913537591 scopus 로고    scopus 로고
    • Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation
    • M.Gambato, S.Lens, M.Navasa, et al. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61(suppl 1):120–131.
    • (2014) J Hepatol , vol.61 , pp. 120-131
    • Gambato, M.1    Lens, S.2    Navasa, M.3
  • 82
    • 84975300976 scopus 로고    scopus 로고
    • Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    • Forthcoming
    • G.Foster, W.Irving, M.Cheung, et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. Forthcoming.
    • J Hepatol
    • Foster, G.1    Irving, W.2    Cheung, M.3
  • 83
    • 84932650978 scopus 로고    scopus 로고
    • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis: a matched analysis
    • V.Saxena, L.Nyberg, M.Pauly, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis: a matched analysis. Hepatology. 2015;62:715–725.
    • (2015) Hepatology , vol.62 , pp. 715-725
    • Saxena, V.1    Nyberg, L.2    Pauly, M.3
  • 84
    • 84933181270 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis
    • K.Reddy, M.Bourlière, M.Sulkowski, et al. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86.
    • (2015) Hepatology , vol.62 , pp. 79-86
    • Reddy, K.1    Bourlière, M.2    Sulkowski, M.3
  • 85
    • 84937064772 scopus 로고    scopus 로고
    • Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and non-cirrhotic patients with chronic hepatitis C virus genotype 1, 4 or 6 Infection: a randomized trial
    • S.Zeuzem, R.Ghalib, K.Reddy, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and non-cirrhotic patients with chronic hepatitis C virus genotype 1, 4 or 6 Infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
    • (2015) Ann Intern Med , vol.163 , pp. 1-13
    • Zeuzem, S.1    Ghalib, R.2    Reddy, K.3
  • 86
    • 84975280004 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter, open-label, randomized, phase 2 study
    • Forthcoming
    • M.Manns, D.Samuel, E.Gane, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicenter, open-label, randomized, phase 2 study. Lancet Infect Dis. Forthcoming.
    • Lancet Infect Dis
    • Manns, M.1    Samuel, D.2    Gane, E.3
  • 88
    • 84934281205 scopus 로고    scopus 로고
    • Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis
    • J.Stine, N.Intagliata, N.Shah, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
    • (2015) Dig Dis Sci , vol.60 , pp. 1031-1035
    • Stine, J.1    Intagliata, N.2    Shah, N.3
  • 89
    • 84975315219 scopus 로고    scopus 로고
    • Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis
    • Forthcoming
    • S.Shibata, T.Umemura, M.Komatsu, et al. Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis. C Hepatol. Forthcoming.
    • C Hepatol
    • Shibata, S.1    Umemura, T.2    Komatsu, M.3
  • 90
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • F.Poordad, C.Hezode, R.Trinh, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–1982.
    • (2014) N Engl J Med , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 91
    • 84975280015 scopus 로고    scopus 로고
    • Liver failure in HIV-HCV coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy
    • Forthcoming
    • A.Marchan, L.Dominguez, P.Kessler, et al. Liver failure in HIV-HCV coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. J Hepatol. Forthcoming.
    • J Hepatol
    • Marchan, A.1    Dominguez, L.2    Kessler, P.3
  • 92
    • 84939799650 scopus 로고    scopus 로고
    • Dual antiviral therapy for HIV and hepatitis C: drug interactions and side effects
    • I.Esposito, P.Labarga, P.Barreiro, et al. Dual antiviral therapy for HIV and hepatitis C: drug interactions and side effects. Expert Opin Drug Saf. 2015;14:1421–1434.
    • (2015) Expert Opin Drug Saf , vol.14 , pp. 1421-1434
    • Esposito, I.1    Labarga, P.2    Barreiro, P.3
  • 93
    • 50649112802 scopus 로고    scopus 로고
    • Treatment predictors of a sustained virologic response in hepatitis B and C
    • A.Kau, J.Vermehren, C.Sarrazin. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–651.
    • (2008) J Hepatol , vol.49 , pp. 634-651
    • Kau, A.1    Vermehren, J.2    Sarrazin, C.3
  • 94
    • 78349296832 scopus 로고    scopus 로고
    • Modelling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV
    • J.Medrano, K.Neukam, N.Rallón, et al. Modelling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with HCV and HIV. Clin Infect Dis. 2010;51:1209–1216.
    • (2010) Clin Infect Dis , vol.51 , pp. 1209-1216
    • Medrano, J.1    Neukam, K.2    Rallón, N.3
  • 95
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • F.Poordad, J.McCone, B.Bacon, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, J.2    Bacon, B.3
  • 96
    • 84865494240 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis C virus infection to boceprevir
    • F.Poordad, J.Bronowicki, S.Gordon, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143:608–618.
    • (2012) Gastroenterology , vol.143 , pp. 608-618
    • Poordad, F.1    Bronowicki, J.2    Gordon, S.3
  • 98
    • 84900326091 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
    • K.Kowdley, S.Gordon, K.Reddy, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.
    • (2014) N Engl J Med , vol.370 , pp. 1879-1888
    • Kowdley, K.1    Gordon, S.2    Reddy, K.3
  • 99
    • 84941564098 scopus 로고    scopus 로고
    • A phase 3 randomized open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naïve and –experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1
    • P.Kwo, N.Gitlin, R.Nahass, et al. A phase 3 randomized open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment-naïve and –experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol. 2015;62(suppl 2):270 [abstract LP14].
    • (2015) J Hepatol , vol.62
    • Kwo, P.1    Gitlin, N.2    Nahass, R.3
  • 100
    • 84898634396 scopus 로고    scopus 로고
    • Therapy for hepatitis C – the costs of success
    • J.Hoofnagle, A.Sherker. Therapy for hepatitis C – the costs of success. N Engl J Med. 2014;370:1552–1553.
    • (2014) N Engl J Med , vol.370 , pp. 1552-1553
    • Hoofnagle, J.1    Sherker, A.2
  • 101
    • 0242624536 scopus 로고    scopus 로고
    • Impact of immunosuppression on immunopathogenesis of liver damage in HCV-infected recipients following liver transplantation
    • G.McCaughan, A.Zekry. Impact of immunosuppression on immunopathogenesis of liver damage in HCV-infected recipients following liver transplantation. Liver Transpl. 2003;9(suppl):21–27.
    • (2003) Liver Transpl , vol.9 , pp. 21-27
    • McCaughan, G.1    Zekry, A.2
  • 102
    • 84970008872 scopus 로고    scopus 로고
    • High serum HCV-RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy
    • Forthcoming, This article reports serum HCV-RNA levels in a large population demonstrating that greater viral loads are uniformly seen in HIV–HCV coinfected versus HCV-monoinfected individuals
    • P.Barreiro, P.Labarga, C.de Mendoza, et al. High serum HCV-RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy. Antivir Ther. Forthcoming.• This article reports serum HCV-RNA levels in a large population demonstrating that greater viral loads are uniformly seen in HIV–HCV coinfected versus HCV-monoinfected individuals.
    • Antivir Ther
    • Barreiro, P.1    Labarga, P.2    de Mendoza, C.3
  • 103
    • 85027940359 scopus 로고    scopus 로고
    • Viral hepatitis: treating hepatitis C in injection drug users
    • V.Soriano, L.Gallego. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–569.
    • (2013) Nat Rev Gastroenterol Hepatol , vol.10 , pp. 568-569
    • Soriano, V.1    Gallego, L.2
  • 104
    • 84895547921 scopus 로고    scopus 로고
    • Towards hepatitis C eradication from the HIV-infected population
    • P.Barreiro, J.V.Fernandez-Montero, C.de Mendoza, et al. Towards hepatitis C eradication from the HIV-infected population. Antivir Res. 2014;105:1–7.
    • (2014) Antivir Res , vol.105 , pp. 1-7
    • Barreiro, P.1    Fernandez-Montero, J.V.2    de Mendoza, C.3
  • 105
    • 84947614518 scopus 로고    scopus 로고
    • Current and evolving treatments of genotype 1 hepatitis C virus
    • S.Alqahtani, M.Sulkowski. Current and evolving treatments of genotype 1 hepatitis C virus. Gastroenterol Clin N Am. 2015;44:825–843.
    • (2015) Gastroenterol Clin N Am , vol.44 , pp. 825-843
    • Alqahtani, S.1    Sulkowski, M.2
  • 106
    • 84884531390 scopus 로고    scopus 로고
    • Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy
    • P.Barreiro, P.Labarga, J.V.Fernández-Montero, et al. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. J Clin Virol. 2013;58:391–395.
    • (2013) J Clin Virol , vol.58 , pp. 391-395
    • Barreiro, P.1    Labarga, P.2    Fernández-Montero, J.V.3
  • 107
    • 84975286079 scopus 로고    scopus 로고
    • Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection
    • Forthcoming
    • J.Vermehren, B.Maasoumy, R.Maan, et al. Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection. Clin Infect Dis. Forthcoming.
    • Clin Infect Dis
    • Vermehren, J.1    Maasoumy, B.2    Maan, R.3
  • 108
    • 84925362379 scopus 로고    scopus 로고
    • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS)
    • M.Bourliere, J.Bronowicki, V.de Ledinghen, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397–404.
    • (2015) Lancet Infect Dis , vol.15 , pp. 397-404
    • Bourliere, M.1    Bronowicki, J.2    de Ledinghen, V.3
  • 109
    • 84952909361 scopus 로고    scopus 로고
    • Sofosbuvir and velpatasvir for HCV genotypes 2 and 3
    • G.Foster, N.Afdhal, S.Roberts, et al. Sofosbuvir and velpatasvir for HCV genotypes 2 and 3. N Engl J Med. 2015;373:2608–2617.
    • (2015) N Engl J Med , vol.373 , pp. 2608-2617
    • Foster, G.1    Afdhal, N.2    Roberts, S.3
  • 110
    • 84975278563 scopus 로고    scopus 로고
    • Hepatitis C therapeutics: pangenotypic therapeutics on the horizon
    • Boston, MA: Feb, [abstract 56]
    • K.Lacombe. Hepatitis C therapeutics: pangenotypic therapeutics on the horizon. CROI 2016. Boston, MA; 2016 Feb 22–25. [abstract 56].
    • (2016) CROI 2016
    • Lacombe, K.1
  • 111
    • 84949089864 scopus 로고    scopus 로고
    • Avoiding treatment failures associated with HCV resistance
    • J.M.Pawlotsky. Avoiding treatment failures associated with HCV resistance. Nature Rev Gastroenterol Hepatol. 2015;12:673–674.
    • (2015) Nature Rev Gastroenterol Hepatol , vol.12 , pp. 673-674
    • Pawlotsky, J.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.